Loading...
•
Dec 31, 2025
Cytek Biosciences Q4 2025 Earnings Report
Cytek Biosciences reported record quarterly revenue for the fourth quarter of 2025, driven by strong instrument sales and recurring revenue growth.
Key Takeaways
Cytek Biosciences achieved record Q4 revenue of $62.1 million, an 8% year-over-year increase. Despite the revenue growth, the company reported a significant net loss of $44.1 million, primarily due to a $38.1 million non-cash valuation allowance against deferred tax assets. Adjusted EBITDA for the quarter was $4.5 million, down from $12.5 million in the prior year due to increased operating expenses.
Achieved record quarterly revenue of $62.1 million, representing 8% year-over-year growth.
Total installed base expanded to 3,664 instruments with 630 placements during the full year 2025.
Recurring revenue (service and reagents) grew 21% in 2025, now accounting for 34% of total revenue.
Net loss was heavily impacted by a $38.1 million non-cash tax valuation allowance, resulting in a GAAP net loss of $44.1 million.
Revenue by Segment
Forward Guidance
Cytek expects full year 2026 revenue to be between $205 million and $212 million, representing 2% to 5% growth over 2025.
Positive Outlook
- Anticipated revenue growth of 2% to 5% for the full year 2026.
- Strong momentum in FSP instrument sales in major markets.
- Improving instrument demand in both the US and EMEA regions.
- Focus on high-margin recurring revenue lines.
- Pipeline of innovative new products like the Aurora Evo and Muse Micro.
Challenges Ahead
- Guidance assumes no change in current foreign currency exchange rates.
- Guidance assumes no change in 2025 US tariff policy.
- Recent softness in EMEA and rest-of-world markets impacted 2025 results.
- Significant increase in operating expenses impacting profitability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...